## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `bpc-157-vs-nsaids`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `bpc-157-vs-nsaids` v23 · content_hash `ca8d7f535af5f25d…` · thread_head genesis
- **thesis (c1):** In controlled animal experiments, the anti-inflammatories and the COX-2 blockers hold back tendon-to-bone healing, and the repair stays weaker for weeks afterwards.
  - c300 [preclinical/active] The damage is worst when the drug is given in the first days, while the body is still setting the repair up.
  - c2 [mechanistic/active] This is not an odd side effect. The repair phase of healing runs on the COX-2 enzyme, and blocking that enzyme is the whole reason the anti-inflammatories work.
  - c301 [mechanistic/active] Putting the downstream signal back, prostaglandin E2 acting on its EP4 receptor, restores the healing the drug had taken away.
  - c3 [human/active] In people, dripping an anti-inflammatory into a working muscle wiped out the rise in satellite cells that exercise normally produces. Those are the stem cells t
  - c4 [preclinical/active] Animal fracture experiments pooled together show these drugs leave healing bone measurably weaker.
  - c5 [human/active] The picture in people is contested. A meta-analysis that adjusted for confounders found no significant rise in fractures failing to knit among people taking the
  - c302 [human/active] Human bone stem cells also turn out to be less sensitive to these drugs than rat cells are.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `bpc-157-vs-nsaids`
- **title:** BPC-157 vs NSAIDs: Repair or Suppress?
- **url:** https://miscsubjects.com/a/bpc-157-vs-nsaids
- **register:** essay
- **updated:** 2026-08-08T18:38:00.019Z
- **tags:** bpc-157, nsaids, tendon, regeneration, disc

## Body

An NSAID is the painkiller already in your cupboard: ibuprofen, naproxen, Advil, Nurofen, Aleve. It is sold over the counter, it is legal everywhere, and a packet costs a few pounds.

BPC-157 is a lab-made copy of a small piece of a protein your own stomach makes. It arrives as a white powder in a sealed glass vial. You add liquid to it and inject it under the skin with an insulin needle. No pharmacy sells it, no country has approved it as a medicine, and everything on the market is labelled for research rather than for people.

## How a torn tendon repairs itself

A tendon is rope: bundles of collagen fibres running in parallel, anchored into bone at each end. Tear it and the body runs a sequence.

First it swells. Swelling is not just the part that hurts — it is the opening instruction. The chemicals that make an injury hot and sore are the same chemicals that call in the cells that clear the wreckage and start laying down new rope.

Then it rebuilds, and rebuilding runs on blood. Blood brings the oxygen and the repair cells. A tendon has very little blood running through it, far less than muscle, which is why a torn tendon takes months to heal and a torn muscle takes weeks.

Last it re-anchors. Where tendon meets bone there is a gristly pad that grips one to the other. That pad is the weakest point of the whole repair and the place a healed tendon tears again.

Three things decide how well you end up: whether the opening instruction is allowed to fire, how much blood reaches the damage, and whether that pad rebuilds properly. Everything below is what each of these two does to those three things.

## What the painkiller does to it

It reduces the pain, and it does that reliably. Take ibuprofen 400 mg and roughly two people in every five get at least half their pain gone who would not have got it from a dummy pill. That figure comes from about 460 separate trials covering roughly 50,000 people, which makes it one of the better-established numbers in medicine.

It produces that relief by shutting down the swelling. That is the same swelling that is the opening instruction, so the relief and the interference are not two separate effects — they are one effect, seen from two ends.

What that does to the tissue has been measured in rats. Both the newer and the older painkillers left a repaired tendon needing less force to tear off the bone again, and less stiff. The gristly pad at the bone was patchy and half-formed, where untreated animals had rebuilt it by four weeks. Giving the drug later does not avoid this: the damage showed up when it was given in the first five days, again at days 6 to 14, and again at days 11 to 20 after a repair.

The steroid injection is the stronger version of the same thing. It relieves for weeks to months, it changes where you end up a year later not at all, and it rebuilds nothing. What it buys is time before a decision about surgery.

Taken for months rather than days, the painkillers carry their own bill: serious stomach bleeds and ulcers run about four times higher on ibuprofen and about four times higher again on naproxen, heart failure risk roughly doubles across the class, and for every thousand people taking one for a year there are three extra heart attacks or strokes, one of them fatal.

## What BPC-157 does to it

It grows new blood vessels into damaged tissue. More vessels means more blood reaching the part of the repair that was starved of it — which is the second of the three things above, and the one a tendon is worst at.

In rats, a tendon cut clean off the heel bone and stitched back came away needing more force to tear again, stiffer, with the collagen fibres lying straight rather than scarred and more vessels grown into the join. The dose was 10 micrograms per kilo of body weight a day. About 150 animal studies exist and they point the same way. In two of them it undid damage a steroid injection had already done to a healing tendon.

In people it has been given in five studies, about 130 people in total. Every one of them was looking for side effects. Not one measured whether anything healed.

At the amount people actually inject — 250 to 500 micrograms a day for four to eight weeks — no trial has ever been run. What exists at that amount is 37 people who wrote down in public what happened to them: 18 said it helped, 5 said partly, 10 said nothing happened, 4 said something got worse. Nobody tested what was in their vials, nobody was randomly assigned, and people who improve write about it more often than people who do not.

## What follows from all of that

[[embed:source:s23]]

**BPC-157 grows new blood vessels into damaged tissue, which is the step the drug's mechanism works against.** In rats, at 10 µg/kg a day, an Achilles cut off the heel bone came back taking more load before it failed, stiffer, with the collagen running straight instead of scarred and more vessels grown in — across roughly 150 animal papers and at least six injury models. In two of those studies it reversed the healing damage a corticosteroid injection had already done. In rats given diclofenac, it blocked the drug's entire gut, liver and brain cascade. In people, five early-phase studies covering about 130 people measured safety and never measured healing; at the dose and duration people actually run — 250 to 500 mcg a day for four to eight weeks — no trial has ever been run at all, and the counted first-person record at that exposure is 37 accounts stating an outcome: 18 helped, 5 partly, 10 nothing, 4 worse.

[[embed:bpc-157]]

Held to one standard, the ledger is this. Neither has a finished controlled trial showing it rebuilds a torn tissue in a person — the peptide has none, and no anti-inflammatory has ever been shown to heal one either. In the animal work where both have been measured, they move the repair in opposite directions: the drug lowers the strength of the healed join, the peptide raises it. And the counted human record at the exposure people actually run belongs only to the peptide, because nobody has run a trial there.

If the only question is what will hurt less in the next four hours, the answer is the drug. The price is a join that fails at a lower load.

Now the two things that make this a real question rather than a rout.

## For back pain specifically, the drug's own trials are unimpressive

The 50,000-participant number comes from post-surgical pain. Back pain is a different question and it has its own trials, and they are far less flattering.

**Acute low back pain.** Cochrane pooled 32 trials, 5,356 participants. Against placebo, anti-inflammatories reduced pain by **7.29 points on a 0–100 scale** (95% CI −10.98 to −3.61), moderate-quality evidence. Disability improved by 2.02 points on a 0–24 scale, high-quality evidence. The reviewers' own summary of that magnitude: "small and probably not clinically relevant." No difference between the newer type of anti-inflammatory and older ones. Almost half the studies were industry-funded.

[[embed:source:s21]]

**Chronic low back pain.** Cochrane, 13 trials. Against placebo, **3.30 points on the same 0–100 scale** (95% CI −5.33 to −1.27), low-quality evidence. Disability, 0.85 points on a 0–24 scale. And this line, which deserves to be read twice: when the reviewers restricted the analysis to trials at low risk of bias, the difference between the drug and placebo got *smaller*.

[[embed:source:s22]]

Set those numbers beside the one intervention with a genuinely large effect for the same condition: structured exercise, pooled across 249 randomised trials, produced a **15.2-point** pain reduction, which cleared the reviewers' pre-set threshold for a clinically important difference.

[[embed:source:s24]]

So the honest ranking for a back, on human trial evidence, is: exercise 15.2 points, anti-inflammatories 7.3 points for acute and 3.3 for chronic, BPC-157 untested. The drug beats the peptide because the peptide has nothing. It loses badly to walking and lifting.

## What each one actually does to the tissue

An anti-inflammatory blocks an enzyme called the newer type of anti-inflammatory. the newer type of anti-inflammatory makes prostaglandins. Prostaglandins are what make an injury swell, throb and hurt. Block the enzyme, lose the prostaglandins, lose the pain. That is the whole drug.

The complication is that prostaglandins are not only a pain signal. They are also the opening instruction of tissue repair — the message that recruits repair cells to a damaged site and starts the rebuilding. One molecule, two jobs. The drug cannot separate them.

BPC-157 runs the opposite way. It is a short chain of fifteen amino acids based on a sequence found in human stomach juice, and in animals it raises VEGF, the signal that grows new blood vessels into damaged tissue, and drives connective-tissue cells to migrate into and repair an injury. It has no pain-blocking action of its own worth speaking of.

One suppresses the signal. The other is studied for accelerating what the signal is calling for. That is the actual axis of this comparison, and neither side of it is automatically the right answer — it depends entirely on what you are trying to buy.

## The case against months of anti-inflammatories is specific, numbered, and not about healing

Most arguments against these drugs are vague and moralising. The real case is none of those things. It is four separate, measured harms, three of which are not in serious dispute.

### The stomach

The largest analysis of individual patient data — 280 trials against placebo covering 124,513 participants, plus 474 head-to-head trials covering 229,296 — put numbers on it by drug. Upper stomach and gut complications, meaning a perforation, obstruction or bleed:

| Drug | Increase in serious stomach bleeds and ulcers vs placebo |
|---|---|
| Naproxen | 4.22× |
| Ibuprofen | 3.97× |
| Diclofenac | 1.89× |
| the newer type of anti-inflammatory drugs (coxibs) | 1.81× |

[[embed:source:s18]]

Note what that table does to the popular story. Naproxen, the one usually recommended as the heart-safe choice, has the *worst* gut number in the set. There is no drug in that column that is free.

The head-to-head randomised trial confirms the direction. PRECISION randomised 24,081 patients with arthritis and raised heart risk to celecoxib, ibuprofen or naproxen for a mean of 20 months. Stomach and gut problems were significantly lower with celecoxib than with either naproxen (p=0.01) or ibuprofen (p=0.002).

[[embed:source:s19]]

### The heart

From the same 124,513-participant analysis:

| Drug | Major heart attacks and strokes | Major coronary events |
|---|---|---|
| Coxibs | 1.37× | 1.76× |
| Diclofenac | 1.41× | 1.70× |
| Ibuprofen | 1.44× (not significant) | 2.22× |
| Naproxen | 0.93× (no increase) | — |

**Heart failure risk was roughly doubled by all of them.** In absolute terms: for every 1,000 people taking a coxib or diclofenac for a year, three extra heart attacks and strokes, one of them fatal.

[[embed:source:s18]]

That is the honest trade-off between the two tables. Naproxen is the kindest to your heart and the harshest on your stomach. Celecoxib is the reverse. There is no free option, and PRECISION found celecoxib was not worse than the other two on heart outcomes at moderate doses, which softened but did not erase the coxib concern.

[[embed:source:s19]]

### The kidneys

Forty studies covering 1,757,118 participants. Long-term use raised the odds of developing or worsening chronic kidney disease: pooled odds ratio 1.24, pooled hazard ratio 1.50. In people who already had kidney disease, the hazard ratio was 1.67.

[[embed:source:s20]]

In PRECISION, kidney events were significantly lower with celecoxib than with ibuprofen (p=0.004).

[[embed:source:s19]]

### The report pile at the regulator, and exactly what it is not

FDA's public reported-harm database holds reports sent in voluntarily by patients, doctors and manufacturers. Queried on 4 August 2026, it holds **283,544 reports naming ibuprofen** and **165,063 naming naproxen**.

Say what those numbers are before reading them. They are counts of reports, not counts of people harmed. There is no denominator anywhere in the system — nobody knows how many people took either drug and reported nothing, and that missing number is the one an incidence rate would need. A report is not a finding that the drug caused the event. The same event can arrive more than once. Reporting rises when a drug is in the news. Nothing in this table is a rate, and it cannot be turned into one.

| Reported event | Reports naming ibuprofen | Reports naming naproxen |
|---|---|---|
| Acute kidney injury | 7,141 | 3,145 |
| Kidney failure | 4,216 | 2,562 |
| Bleeding in the gut | 2,689 | 1,486 |
| Heart attack | 1,781 | 1,770 |
| Stomach ulcer | 1,394 | 867 |
| Black stool from a gut bleed | 1,208 | 478 |
| Heart failure | 634 | 305 |
| Bleeding from the stomach lining | 622 | 489 |
| Ulcer in the first part of the small intestine | 614 | 359 |

[[embed:source:s42]]

Two things are worth taking from it. The kidney rows sit above the gut rows for both drugs, which is the opposite of the ordering most people carry in their heads, and it lines up with the direction of the 1,757,118-participant kidney analysis rather than contradicting it. And the single most reported term for both drugs is not a harm at all: **"drug ineffective" — 27,383 times for ibuprofen and 22,584 for naproxen.** Set that beside the Cochrane back-pain numbers at the top of this page and it is the same finding arriving from the other end of the evidence pyramid.

The controlled trials above give you rates. This gives you the shape of what lands when something goes wrong. Use it for the second and never for the first.

### Tendon and soft-tissue healing — the one that is genuinely contested

This is the argument most often made and least often made carefully. **In animals it is consistent and specific.** In a rotator cuff repair model, both an older anti-inflammatory (indomethacin) and a the newer type of anti-inflammatory one (celecoxib) produced significantly weaker tendon-to-bone healing than untreated controls, out to eight weeks.

[[embed:source:s1]]

**The timing pattern is the strongest part of the case.** Give ibuprofen during the early repair window and tendon healing is measurably worse; give the same drug later and the effect fades. That is exactly the pattern you would predict if the drug is interrupting the initial repair instruction rather than merely masking pain.

[[embed:source:s3]]

**Bone shows it too.** Pooled animal data show these drugs measurably reduce the mechanical strength of healing fractures.

[[embed:source:s6]]

**The mechanism is not a coincidence.** Knock out the newer type of anti-inflammatory in mice and fractures heal badly. Restore the downstream prostaglandin signal and the healing is rescued. The enzyme the drug exists to block is the same enzyme repair runs on.

[[embed:source:s8]]

**It reaches human repair cells.** In a human study, infusing an anti-inflammatory locally during exercise abolished the normal rise in muscle satellite cells — the stem cells that rebuild muscle after loading.

[[embed:source:s7]]

**And now the counter-evidence, which is real.** A study that pools other studies of human fracture outcomes that adjusted for confounders found **no significant increase in fracture non-union** among people taking these drugs.

[[embed:source:s5]]

**There is even a species-level reason it might not translate.** Human skeletal stem cells were directly compared with rodent ones and turned out to be substantially less dependent on the newer type of anti-inflammatory for their function.

[[embed:source:s4]]

So the fair verdict, stated as a rate rather than a mood: **animal healing impairment is consistently reproduced; human cellular repair signals are measurably blunted; human clinical healing outcomes show no proven harm.** Anyone claiming these drugs are proven to wreck human healing is overstating. Anyone claiming the concern is invented is ignoring the timing data and the knockout mice.

## Why the argument sharpens when the injury is one the drug's own trials do badly on

A herniated disc is the one case where the healing question is not theoretical, because the mechanism that removes a herniation *is* an inflammatory mechanism.

Displaced disc material meets blood supply and immune cells for the first time. Immune cells digest it, new blood vessels grow in to supply the operation, and about 70% of herniations reabsorb on their own within roughly six months.

[[embed:herniated-disc]]

Suppress that inflammation continuously and you are working against the clearance. This is not purely inference: corticosteroids inhibited the bulge shrinking on its own in animal studies, and a clinical series that deliberately withheld anti-inflammatory drugs reported the bulge shrinking on its own in every patient.

[[embed:source:s17]]

That evidence is a case series, not a randomised trial, and it should be weighted as such. But it points the same direction as the tendon timing data, and it is the reason "a few days for a flare" and "eight months of daily tablets" are different decisions rather than different doses of the same decision.

The slower wear process behind many of these discs is a separate question with its own numbers, and it changes what a long course of anything is being asked to do:

[[embed:degenerative-disc-disease]]

## What BPC-157 actually has, listed without inflation

**In animals, the tendon results are the strongest thing it has.** A transected rat Achilles tendon treated with BPC-157 came back with greater load-to-failure and better collagen organisation than controls.

[[embed:source:s10]]

**The cellular behaviour matches.** Tendon cells showed better outgrowth, survival and migration — the three behaviours that define active repair rather than scarring over.

[[embed:source:s11]]

**And the mechanism is the mirror image of the drug's.** BPC-157 raises VEGF and drives new blood vessel growth into healing muscle and tendon — the same vascular pathway that the newer type of anti-inflammatory blockade suppresses.

[[embed:source:s12]]

**It protects against the drug's own gut damage, in rats.** Given alongside diclofenac, BPC-157 counteracted the stomach and gut, liver and brain lesions the drug caused.

[[embed:source:s13]]

**The same protection held when adjuvant arthritis and drug-induced gut lesions were put on the animal together.**

[[embed:source:s14]]

**What none of that is:** a human result. Every item above is a rodent. There is no completed randomised controlled trial of BPC-157 in a human injury, no dose established for a human tendon, and no study of any kind against a human disc.

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:what-are-peptides-herniated-disc]]

## Seven people on long-term anti-inflammatories, counted

**Seven first-person accounts from X, counted.** **Four of the seven reported a harm. One was warned off by a doctor before anything went wrong. One reported no problems over more than ten years. One is worried and getting tested, with no result back yet.**

Read this panel knowing exactly what is wrong with it: people post about the ulcer that sent them to hospital, not about the uneventful decade. The harm fraction here is not the population rate — the population rate is in the tables above, and it is a 4× relative increase on a small absolute base, not four in seven. This panel tells you what the harm looks like when it lands, not how often it lands.

**Reported a harm — 4 of 7.**

Kidney filtration flagged on bloodwork after years of six tablets a day:

[[embed:source:s25]]

A stomach bleed that lasted a year, and twelve years of avoiding the whole drug class afterwards:

[[embed:source:s26]]

Five tablets a day for five years for back pain, and a stomach that can no longer tolerate the drug at all:

[[embed:source:s27]]

An ulcer, black stool, and an emergency room:

[[embed:source:s28]]

**Warned off, no harm reported yet — 1 of 7.** Nearly two years of naproxen with a stomach-protecting drug alongside it, then a new doctor capping it at six months:

[[embed:source:s29]]

**No problems — 1 of 7.** Over ten years of use, including long continuous stretches, and no reported issue:

[[embed:source:s30]]

**Worried, no result yet — 1 of 7.** Years of heavy use, now getting kidney and liver function tested:

[[embed:source:s31]]

## Ten people on BPC-157, counted

**Ten first-person accounts from X**, all self-reported, none verified, none from a trial. **Six said it helped. One said it helped and raised the possibility of placebo himself. Two said it did not work. One reported no outcome either way. Nobody reported a serious harm, and the only physical complaint in the set was at an injection site.**

Two of the six positive accounts carry either a supplier link or a follow-me pitch attached to the post. That is not proof they are false, but it is a selection problem you should hold in mind while reading them.

**Said it helped — 6 of 10.**

A dried-out lower disc plus a year-old biceps tendon problem, six weeks of BPC-157 and TB-500 — tendon and shoulder resolved, disc improved but explicitly still needing physiotherapy:

[[embed:source:s32]]

Elbow tendon pain of months' standing, injected locally at the site:

[[embed:source:s33]]

A two-and-a-half-year knee injury the poster says nothing else had fixed:

[[embed:source:s34]]

Shoulder and joint pain on the BPC-157 plus TB-500 combination — note this post also links a supplier:

[[embed:source:s35]]

A rotator cuff for which surgery had been recommended, two eight-week cycles, surgery avoided — note this post ends in a follow-me pitch:

[[embed:source:s36]]

Two months, rotator cuff quiet during training, and heartburn gone as a side effect:

[[embed:source:s37]]

**Helped, but he flagged placebo himself — 1 of 10.** This is the most intellectually honest account in the set, and it is worth more than the enthusiastic ones:

[[embed:source:s38]]

**Said it did not work — 2 of 10.**

Ten years of on-and-off use and a flat verdict, including new tendon pain appearing while on it:

[[embed:source:s39]]

Eight weeks for a shoulder, judged not a success — with an interesting detail: stomach problems he had stopped noticing came back two weeks after stopping, which is the one place his account supports the gut-protective animal data even while rejecting the injury claim:

[[embed:source:s40]]

**No outcome reported — 1 of 10.** An injection-site problem from using too large a needle.

[[embed:source:s41]]

**What ten accounts can and cannot establish.** They cannot establish that it works — there is no control group, no blinding, no independent measurement, and a heavy bias toward people who bought the thing and want it to have worked. What they do establish, honestly: the reported experience is not uniformly positive, two of ten users describe no benefit at all, one of the enthusiasts volunteered placebo as an explanation unprompted, and nobody in this set reported a serious reported harm. Hold that against the 50,000-participant table at the top of this page and the size of the gap is the point.

## What is legal, which is a separate question from what works

**BPC-157 is not an approved drug anywhere.** Its regulatory position has moved recently, so the specific dates matter more than the summary. FDA placed it in Category 2 of the 503A bulk substances list in September 2023, barring pharmacy compounding. It was off all three categories by the 14 May 2026 revision after the nominations were withdrawn. In July 2026 FDA's own briefing document recommended against adding it; on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend adding it anyway, against FDA staff. It is not on the 503B outsourcing-facility list either.

**It is prohibited in sport at all times.** WADA's 2026 Prohibited List names BPC-157 explicitly under S0, non-approved substances — in and out of competition, not only on competition day. The US Department of Defense lists it on its Prohibited Dietary Supplement Ingredients List and states plainly that it is not a dietary ingredient but an unapproved drug, at any route.

**What it is sold as:** research chemical, research use only. That is a shipping label, not a legal category granting you permission to use it.

[[embed:bpc-157]]

**Ibuprofen and naproxen are over-the-counter medicines** with approved labels, approved dose ceilings, and pharmacist advice attached. That difference is not a footnote — it is the reason one of them has 50,000 participants of evidence behind it and the other does not.

## The decision table

| Your situation | What the evidence supports | What the evidence does not support | Legal position |
|---|---|---|---|
| Acute pain in the first few days, any injury | A short course of an anti-inflammatory. NNT 2.5 for ibuprofen 400 mg on at least 50% pain relief | That it speeds your healing, or that avoiding it makes you heal better | Over the counter |
| Acute back pain specifically | The same short course, with realistic expectations — 7.3 points on a 0–100 scale, which the reviewers called probably not clinically relevant | That it will do much. Movement outperforms it by roughly double | Over the counter |
| Chronic back pain, months in | Exercise. 15.2 points across 249 trials, against 3.3 points for the drug | Daily long-term anti-inflammatories as the plan. The effect shrinks in the least-biased trials and the harm accumulates | Over the counter, but this is the use with the harm tables attached |
| A herniated disc actively reabsorbing | Short courses to enable movement | Continuous suppression for months. Steroids inhibited the bulge shrinking on its own in animal studies; one series avoiding these drugs saw the bulge shrinking on its own in every patient | Over the counter |
| You already have stomach disease or a bleed history | Avoiding the older drugs. Coxibs 1.81× vs ibuprofen 3.97× and naproxen 4.22× for serious stomach bleeds and ulcers | That any of them is gut-neutral | Prescription for coxibs in most places |
| You have heart disease or heart failure | Caution across the whole class. Heart failure risk roughly doubled by all of them; naproxen alone did not raise heart attacks and strokes | That the choice of drug removes the risk | Over the counter, which does not mean low-risk here |
| You have kidney disease | Avoiding long-term use. Hazard ratio 1.67 for progression in people who already have it | That short courses carry the same risk as chronic use | Over the counter |
| Tendon or soft-tissue injury where healing is the goal | Load management, progressive rehabilitation, and using pain relief sparingly in the first repair window | Either extreme. Animal harm is consistent; human non-union data shows none | Over the counter |
| You are considering BPC-157 for an injury | Nothing, in humans. Animal tendon repair is real and consistent; that is the entire honest case | Any human dose, any human timeline, any disc claim, any comparison of its how big the difference was to the drug's | Not approved anywhere. Banned in sport at all times. Prohibited for US service members |
| You are a competing athlete | Whatever is on your sport's permitted list | Using BPC-157 under any framing, including "research use only" | WADA S0, strict liability, in and out of competition |

## The one-line version of each side

**For the drug:** it demonstrably relieves pain in humans at scale, it is legal, it is cheap, and the healing concern is unproven in human outcomes. Its costs are measured, drug-specific, and rise with duration rather than dose alone.

**For the peptide:** it has a coherent repair mechanism, consistent animal tendon results, and animal evidence that it protects the gut lining the drug damages. It has no human trial for any injury, no established dose, no legal approval, and a user-report base with two in ten reporting nothing at all.

Those two paragraphs are not equivalent, and nothing above has tried to make them equivalent. One is a medicine with a known how big the difference was and a known bill. The other is an interesting hypothesis being taken by a lot of people ahead of its evidence.

*What is compared above is the state of the evidence. It is not medical advice and not a dosing recommendation. Do not stop a prescribed medicine on the basis of a web page. BPC-157 is sold for research use only, is not approved for human use in any jurisdiction, and is prohibited in sport at all times.*


## Claims (48 of 70 ranked)

- **c30** [mechanistic w=?] In September 2023 the FDA put BPC-157 in Category 2 of the 503A bulk substances list, which barred pharmacies from compounding it.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c31** [mechanistic w=?] WADA's 2026 Prohibited List names BPC-157 under S0, its non-approved substances category, banned both in and out of competition.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c330** [mechanistic w=?] By the 14 May 2026 revision it had come off all three categories, because the nominations behind it were withdrawn.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c331** [mechanistic w=?] In July 2026 the FDA's own briefing document recommended against adding it back.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c332** [mechanistic w=?] On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding it anyway, against the FDA staff position.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c333** [mechanistic w=?] It is not on the 503B list either.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c334** [mechanistic w=?] The US Department of Defense puts it on its Prohibited Dietary Supplement Ingredients List and says plainly that it is not a dietary ingredient but an unapproved drug, by any route.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c335** [mechanistic w=?] Research-use-only printed on a vial is a shipping label, not a permission.
  - who_claims: opus-5 (claude-code)
  - slot: limitations
- **c3** [human w=?] In people, dripping an anti-inflammatory into a working muscle wiped out the rise in satellite cells that exercise normally produces. Those are the stem cells that rebuild muscle.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s7
- **c5** [human w=?] The picture in people is contested. A meta-analysis that adjusted for confounders found no significant rise in fractures failing to knit among people taking these drugs.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s5, s4
- **c6** [human w=?] Taking these drugs for years brings a well-established risk of bleeding and ulcers in the gut, and the risk climbs with the dose.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s15
- **c10** [human w=?] For sudden muscle and joint pain the anti-inflammatories are still the first thing the guidelines reach for, and they earned that.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s16
- **c11** [human w=?] A Cochrane overview gathered up 39 systematic reviews, covering roughly 460 randomised trials and about 50,000 people who had taken a painkiller.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s23
- **c12** [human w=?] BPC-157 has never finished a randomised controlled trial in a human being for any injury at all. Not tendon, not muscle, not disc, not joint.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_unknown
  - sources: s10, s11, s12
- **c13** [human w=?] For sudden low back pain, Cochrane pooled 32 trials and 5,356 people and found the anti-inflammatories took 7.29 points off pain on a 0 to 100 scale (95% CI -10.98 to -3.61, moderate quality).
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s21
- **c14** [human w=?] For back pain that has dragged on, Cochrane pooled 13 trials and the anti-inflammatories beat placebo by 3.30 points on a 0 to 100 scale (95% CI -5.33 to -1.27, low quality).
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s22
- **c15** [human w=?] Structured exercise, pooled across 249 randomised trials, took 15.2 points off long-running low back pain and cleared the bar the reviewers had set in advance for a difference that matters.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s24
- **c16** [human w=?] One analysis went back to the individual patients in 280 placebo-controlled trials covering 124,513 people, plus 474 head-to-head trials covering 229,296 more.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s18
- **c17** [human w=?] The PRECISION trial put 24,081 people who had arthritis and a raised heart risk onto celecoxib, ibuprofen or naproxen for an average of 20 months.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s19
- **c18** [human w=?] In that same 124,513-person analysis, major events in the blood vessels came out 1.37 times more likely on the coxibs, 1.41 times on diclofenac and 1.44 times on ibuprofen, which did not reach significance, with naproxen sitting at 0.93.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s18
- **c19** [human w=?] Forty studies covering 1,757,118 people found that taking anti-inflammatories long term raised the odds of getting long-running kidney disease, or of making existing kidney disease worse.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s20
- **c23** [human w=?] The one human experiment in this group ran the same test in reverse. An anti-inflammatory dripped straight into working muscle wiped out the rise in satellite cells that loading normally produces.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s7
- **c24** [human w=?] Against all of that, a meta-analysis of human fracture outcomes that adjusted for confounders found no significant rise in fractures failing to knit among people on these drugs.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s5, s4
- **c25** [human w=?] In animal work, steroids held the herniated disc back from shrinking away on its own.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s17
- **c32** [human w=?] The healing harm from the anti-inflammatories reproduces consistently in animals.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s1, s3, s5, s6, s7
- **c302** [human w=?] Human bone stem cells also turn out to be less sensitive to these drugs than rat cells are.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s5, s4
- **c303** [human w=?] Which one you take matters a great deal. Ketorolac runs about 20 times the risk, and celecoxib is the lowest of the group.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s15
- **c306** [human w=?] On that evidence, ibuprofen 400 mg clears at least 50% of the pain in one extra person for every 2.5 people who take it.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s23
- **c307** [human w=?] Fast-acting ibuprofen 200 mg brings that number down to 2.1, and ibuprofen 200 mg taken with paracetamol 500 mg brings it to 1.6.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s23
- **c308** [human w=?] What exists instead is rat work, a handful of early safety studies in people for other conditions, and what people say happened to them.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_unknown
  - sources: s10, s11, s12
- **c309** [human w=?] Disability moved 2.02 points on a 0 to 24 scale, and the reviewers called both of those effects small and probably not meaningful to the person feeling them.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s21
- **c310** [human w=?] Disability moved 0.85 points on a 0 to 24 scale, and when the reviewers kept only the trials at low risk of bias, the gap shrank further.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s22
- **c311** [human w=?] That is roughly double what the drugs managed for sudden back pain, and nearly five times what they managed for the long-running kind.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s24
- **c312** [human w=?] Serious trouble at the top of the gut came out 4.22 times more likely on naproxen, 3.97 times on ibuprofen, 1.89 times on diclofenac and 1.81 times on the coxibs.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s18
- **c313** [human w=?] Gut events came out significantly lower on celecoxib than on naproxen (p = 0.01) or on ibuprofen (p = 0.002).
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s19
- **c314** [human w=?] Heart failure risk was roughly doubled by every one of them.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s18
- **c315** [human w=?] Put as plain counts, for every 1,000 people who take a coxib or diclofenac for a year, three have an extra major blood vessel event and one of those three dies of it.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s18
- **c316** [human w=?] The pooled odds ratio came out at 1.24 and the pooled hazard ratio at 1.50, rising to 1.67 in people whose kidneys were already damaged.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s20
- **c320** [human w=?] Human bone stem cells put side by side with rat ones leaned far less on COX-2, which is a species-level reason the animal result may not carry over.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s5, s4
- **c321** [human w=?] A clinical series that deliberately withheld anti-inflammatory drugs reported the disc shrinking away on its own in every single patient.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s17
- **c322** [human w=?] That was a case series and not a randomised trial, and it should carry only the weight a case series carries.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s17
- **c336** [human w=?] In people, the repair signals measured at the cell level are measurably blunted.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s1, s3, s5, s6, s7
- **c337** [human w=?] In people, the healing outcomes that actually get measured in a clinic show no proven harm.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s1, s3, s5, s6, s7
- **c1** [preclinical w=?] In controlled animal experiments, the anti-inflammatories and the COX-2 blockers hold back tendon-to-bone healing, and the repair stays weaker for weeks afterwards.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s1, s3, s2
- **c4** [preclinical w=?] Animal fracture experiments pooled together show these drugs leave healing bone measurably weaker.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s6
- **c7** [preclinical w=?] In rat tendon experiments BPC-157 pushes repair forward, so the tendon carries more load before it fails and lays down better collagen.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s10, s11
- **c9** [preclinical w=?] In rat poisoning experiments, BPC-157 undoes the gut and organ damage that the anti-inflammatory drugs cause.
  - who_claims: Fable 5 (Claude Code)
  - slot: what_is_known
  - sources: s13, s14
- **c20** [preclinical w=?] In an animal rotator cuff repair, both indomethacin and celecoxib left the tendon-to-bone join significantly weaker than in untreated animals, and it was still weaker out at eight weeks.
  - who_claims: opus-5 (claude-code)
  - slot: what_is_known
  - sources: s1

## Voxel graph (70 atoms · 221 edges)
- full graph: https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (40 of 42)
- chain valid: yes · head: `ee2b10ba8a567e29`

### s1 · pubmed
- title: Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing
- url: https://pubmed.ncbi.nlm.nih.gov/16210573/
- quote: There were significantly lower failure loads in the celecoxib and indomethacin groups compared with the control groups at 2, 4, and 8 weeks (P < .001)
- claim_ids: c1
- hash: `10da630fc7b601f4`

### s2 · pubmed
- title: NSAID therapy effects on healing of bone, tendon, and the enthesis
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC3764618/
- quote: Numerous animal studies have demonstrated a consistent negative effect of NSAID treatment on endochondral ossification during fracture healing.
- claim_ids: c1, c2
- hash: `6195401ea20a004f`

### s3 · pubmed
- title: The detrimental effects of systemic Ibuprofen delivery on tendon healing are time-dependent
- url: https://pubmed.ncbi.nlm.nih.gov/23982408/
- quote: Early administration of ibuprofen in the postoperative period was detrimental to tendon healing, while delayed administration did not affect tendon healing.
- claim_ids: c1
- hash: `74343a921af7d7ca`

### s4 · pubmed
- title: Cross-species comparisons reveal resistance of human skeletal stem cells to inhibition by NSAIDs
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC9454294/
- quote: human SSCs (hSSC) downregulated COX2 expression during differentiation and showed impaired osteogenic capacity if COX2 was lentivirally overexpressed.
- claim_ids: c5
- hash: `2ee1555d35e7e147`

### s5 · pubmed
- title: Do NSAIDs affect bone healing rate, delay union, or cause non-union: an updated systematic review and meta-analysis
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11420001/
- quote: There was no significant difference in the rates of non-union or delayed union between NSAID users and non-users (pooled adjusted OR = 1.11; 95% CI: 0.99-1.23)
- claim_ids: c5
- hash: `7df8e5ef9212a17f`

### s6 · pubmed
- title: NSAIDs and bone healing in animal models - a systematic review and meta-analysis
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC8268344/
- quote: NSAIDs administration decreased the biomechanical properties of healing bones after fracture surgery in comparison to the control group.
- claim_ids: c4
- hash: `86964d7982aa6975`

### s7 · pubmed
- title: Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise
- url: https://pubmed.ncbi.nlm.nih.gov/19713429/
- quote: The number of Pax7(+) cells was unchanged in the leg muscles exposed to the NSAID (0.07 +/- 0.01).
- claim_ids: c3
- hash: `aefb763b1c62b75f`

### s8 · pubmed
- title: Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4
- url: https://pubmed.ncbi.nlm.nih.gov/19628768/
- quote: The EP4 agonist markedly improved the impaired healing in COX-2(-/-) mice ... a near complete reversal of bone formation
- claim_ids: c2, c8
- hash: `d36bdc9fe8e9ef04`

### s9 · pubmed
- title: Reduced COX-2 Expression in Aged Mice Is Associated With Impaired Fracture Healing
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC3276605/
- quote: Cyclooxygenase 2 (COX-2), the inducible regulator of prostaglandin E2 (PGE2) synthesis, is critical for normal bone repair.
- claim_ids: c2
- hash: `23bb5491d06eb0cf`

### s10 · pubmed
- title: Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and stimulates tendocyte growth in vitro
- url: https://pubmed.ncbi.nlm.nih.gov/14554208/
- quote: pentadecapeptide BPC 157 fully improves recovery: (i) biomechanically, increased load of failure, load of failure per area and Young's modulus of elasticity
- claim_ids: c7
- hash: `51af90a8551727df`

### s11 · pubmed
- title: The promoting effect of BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
- url: https://pubmed.ncbi.nlm.nih.gov/21030672/
- quote: BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration
- claim_ids: c7
- hash: `f5a5a3fa3b4a384f`

### s12 · pubmed
- title: Modulatory effect of BPC 157 on angiogenesis in muscle and tendon healing
- url: https://pubmed.ncbi.nlm.nih.gov/20388964/
- quote: BPC 157 stimulating angiogenesis by up-regulating VEGF expression.
- claim_ids: c8
- hash: `1e821859ff8033f2`

### s13 · pubmed
- title: BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced GI, liver, and encephalopathy lesions
- url: https://pubmed.ncbi.nlm.nih.gov/21295044/
- quote: may encourage its further use as a therapy to counteract diclofenac- and other NSAID-induced toxicity.
- claim_ids: c9
- hash: `5fbbe156c4841818`

### s14 · pubmed
- title: BPC 157 positively affects both NSAID-induced gastrointestinal lesions and adjuvant arthritis in rats
- url: https://pubmed.ncbi.nlm.nih.gov/9403784/
- quote: Given with the investigated NSAIAs, BPC 157 consistently reduced the otherwise prominent lesions in the stomach ... as well as the lesions in the small intestine
- claim_ids: c9
- hash: `6fb170120e1fc87c`

### s15 · pubmed
- title: NSAIDs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12746519/
- quote: ketorolac showed the highest risk (OR 20.67, 95% CI: 14.56-29.34)
- claim_ids: c6
- hash: `6fca5f2bbe021a78`

### s16 · pubmed
- title: Management of Acute Pain From Non-Low Back Musculoskeletal Injuries: ACP/AAFP Clinical Guideline
- url: https://pubmed.ncbi.nlm.nih.gov/32805126/
- quote: clinicians treat patients with acute pain from non-low back, musculoskeletal injuries with topical nonsteroidal anti-inflammatory drugs (NSAIDs) ... as first-line therapy
- claim_ids: c10
- hash: `e5642db09702f309`

### s17 · pubmed
- title: Lumbar Disc Herniation Resorption: When and How Does It Occur?
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12890389/
- quote: controlled inflammatory responses are necessary for disc resorption ... standard anti-inflammatory treatments may paradoxically impede this process.
- hash: `378dbfe65853810d`

### s18 · pubmed
- title: Vascular and upper gastrointestinal effects of NSAIDs: meta-analyses of individual participant data from randomised trials (Lancet 2013, PMID 23726390)
- url: https://pubmed.ncbi.nlm.nih.gov/23726390/
- summary: 280 placebo-controlled trials (124,513 participants) plus 474 head-to-head trials (229,296). The definitive per-drug harm table for heart, heart failure and upper gut.
- quote: Major vascular events were increased by about a third by a coxib (rate ratio [RR] 1.37) or diclofenac (1.41)... Ibuprofen also significantly increased major coronary events (2.22), but not major vascular events (1.44). Naproxen did not significantly increase major vascular events (0.93)... Heart failure risk was roughly doubled by all NSAIDs. All NSAID regimens increased upper gastrointestinal complications (coxibs 1.81; diclofenac 1.89; ibuprofen 3.97; and naproxen 4.22).
- hash: `0bd5346b10c72b31`

### s19 · pubmed
- title: Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis — PRECISION (NEJM 2016, PMID 27959716)
- url: https://pubmed.ncbi.nlm.nih.gov/27959716/
- summary: 24,081 patients randomised head to head for a mean of 20 months. The largest direct comparison between the three drugs on heart, gut and kidney outcomes.
- quote: A total of 24,081 patients were randomly assigned to the celecoxib group... the naproxen group... or the ibuprofen group for a mean treatment duration of 20.3 months... The risk of gastrointestinal events was significantly lower with celecoxib than with naproxen (P=0.01) or ibuprofen (P=0.002); the risk of renal events was significantly lower with celecoxib than with ibuprofen (P=0.004)... At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with 
- hash: `38863dfb0c55aa57`

### s20 · pubmed
- title: NSAIDs: what is the actual risk of chronic kidney disease? A systematic review and meta-analysis (Rom J Intern Med 2025, PMID 39412516)
- url: https://pubmed.ncbi.nlm.nih.gov/39412516/
- summary: 40 studies, 1.76 million participants. Long-term use raises the odds of developing or worsening chronic kidney disease, worst in those who already have it.
- quote: Forty studies with a total of 1757118 participants were included... The pooled odds ratio was 1.24 (95% CI: 1.11-1.39), and the pooled hazard ratio was 1.50 (95% CI: 1.31-1.7). The pooled hazard ratio (HR) for individuals with no CKD at baseline was 1.31, while for those with preexisting CKD, the HR was significantly higher at 1.67.
- hash: `97b6e1e1bfe27186`

### s21 · pubmed
- title: Non-steroidal anti-inflammatory drugs for acute low back pain (Cochrane 2020, PMID 32297973)
- url: https://pubmed.ncbi.nlm.nih.gov/32297973/
- summary: 32 trials, 5,356 participants. For acute back pain specifically, the drug beats placebo by 7.3 points on a 100-point scale, which the reviewers themselves call probably not clinically relevant.
- quote: We included 32 trials, with a total of 5356 participants... There is moderate quality evidence that NSAIDs are slightly more effective in short-term (<= 3 weeks) reduction of pain intensity (visual analogue scale, 0 to 100) than placebo (mean difference (MD) -7.29 (95% CI -10.98 to -3.61); 4 RCTs, N = 815)... The magnitude of these effects is small and probably not clinically relevant.
- hash: `3172c5960a9de7b0`

### s22 · pubmed
- title: Non-steroidal anti-inflammatory drugs for chronic low back pain (Cochrane 2016, PMID 26863524)
- url: https://pubmed.ncbi.nlm.nih.gov/26863524/
- summary: 13 trials. For chronic back pain the drug beats placebo by 3.3 points on a 100-point scale, and the effect shrinks further in the least-biased trials.
- quote: There is low quality evidence that NSAIDs are more effective than placebo, with a mean difference in pain intensity score from baseline of -3.30 (95% CI -5.33 to -1.27) on a 0 to 100 visual analogue scale... When we only included RCTs at low risk of bias, differences in effect between NSAIDs and placebo were reduced.
- hash: `3b5ef68bd7f2ae32`

### s23 · pubmed
- title: Single dose oral analgesics for acute postoperative pain in adults — an overview of Cochrane reviews (Cochrane 2015, PMID 26414123)
- url: https://pubmed.ncbi.nlm.nih.gov/26414123/
- summary: 39 Cochrane reviews, ~460 trials, ~50,000 participants. The scale of human evidence behind ibuprofen as a painkiller, and the exact number needed to treat.
- quote: The overview included 39 separate Cochrane Reviews with 41 analyses of single dose oral analgesics tested in acute postsurgical conditions, with results from about 50,000 participants in approximately 460 individual studies... Good (low) NNTs were obtained with ibuprofen 200 mg plus paracetamol 500 mg (NNT compared with placebo 1.6), ibuprofen fast acting 200 mg (2.1)... For comparison, ibuprofen acid 400 mg had an NNT of 2.5 (2.4 to 2.6).
- hash: `71e132983a555d77`

### s24 · pubmed
- title: Exercise therapy for chronic low back pain (Cochrane 2021, PMID 34580864)
- url: https://pubmed.ncbi.nlm.nih.gov/34580864/
- summary: 249 randomised trials. The comparator that matters: exercise produces roughly double the acute-back-pain effect of the drug and five times its chronic-back-pain effect.
- quote: We found moderate-certainty evidence that exercise treatment is more effective for treatment of chronic low back pain compared to no treatment, usual care or placebo comparisons for pain outcomes at earliest follow-up (MD -15.2, 95% CI -18.3 to -12.2), a clinically important difference.
- hash: `741e6e2fc3ec9027`

### s25 · x
- title: Six ibuprofen a day for years, kidney filtration flagged on bloodwork (anecdotal)
- url: https://x.com/rjust1421/status/2079732817420816700
- summary: Anecdotal, single account. Reported kidney harm after years of high daily dosing.
- quote: I took 6 ibuprofen daily for years until I retired. Don't need them anymore but last bloodwork showed filtration issues.
- hash: `ec2b29b64a9cd26f`

### s26 · x
- title: A stomach bleed that lasted a year, then twelve years avoiding the whole drug class (anecdotal)
- url: https://x.com/TheFengHunter/status/2065052345642205232
- summary: Anecdotal, single account. Reported gastrointestinal bleed, and the long shadow it casts on later treatment decisions.
- quote: Indomethacin gave me a stomach bleed that lasted a year bc of polypharmacy. I am currently taking a short course of naproxen bc of shoulder trauma from a sleep-related movement disorder. This is the first time in 12 years I have taken an NSAID. I begged for one. A little worried.
- hash: `f66d8c7e9ddecb13`

### s27 · x
- title: Five ibuprofen a day for five years for back pain, stomach no longer tolerates it (anecdotal)
- url: https://x.com/jbf789/status/2060150691117605310
- summary: Anecdotal, single account. Reported gastrointestinal harm; the exposure is exactly the long-term back-pain use pattern this page argues against.
- quote: I took 5 Ibuprofen a day for 5 years...for back pain. Now I it hurts my stomach terribly! I can't tolerate it, at all.
- hash: `b86e601ff02f7153`

### s28 · x
- title: Ulcer, black stool, emergency room (anecdotal)
- url: https://x.com/DadStrayer/status/2051426299843870966
- summary: Anecdotal, single account. Reported gastrointestinal bleed requiring emergency care.
- quote: Be careful with the ibuprofen. I started taking so much that it caused an ulcer in my stomach and I ended up in an emergency room due to have black stool.
- hash: `4d899ceb63eafed2`

### s29 · x
- title: Two years of naproxen for spinal pain, then a six-month cap (anecdotal)
- url: https://x.com/BraisbyI/status/2076624300556112226
- summary: Anecdotal, single account. No harm reported yet; included because it shows how differently two clinicians can treat the same duration question.
- quote: I took Naproxen for almost 2 years to help with spinal pain, and as you say, I also had to take omeprazole. When I moved house recently my new Dr. told me that I was only allowed Naproxen for a 6 month period or it could do irrepealable damage?
- hash: `085de0a7d0b4cf3e`

### s30 · x
- title: Over ten years of use, no reported problems (anecdotal)
- url: https://x.com/meetjeo/status/2036117578112766127
- summary: Anecdotal, single account. The negative-for-harm case, included because the panel would be dishonest without it — though the harm tables show the risk is real even when an individual escapes it.
- quote: I've been taking ibuprofen well over 10 years, even for long controlled periods of time. It's not going to cause any issues unless it's misused.
- hash: `f763577c8299ee01`

### s31 · x
- title: Years of heavy use, kidney and liver tests pending (anecdotal)
- url: https://x.com/BamaDarling/status/2080126143349346337
- summary: Anecdotal, single account. Outcome not yet known.
- quote: I've been taking so much ibuprofen for Years, I'm getting my kidney & liver functions tested as well!
- hash: `ef5883d64eaba9dc`

### s32 · x
- title: A dried-out lower disc plus a year-old biceps tendon problem, six weeks of BPC-157 and TB-500 (anecdotal)
- url: https://x.com/MuroCrypto/status/2083184469956059529
- summary: Anecdotal, single account, self-reported. Tendon and shoulder resolved; disc improved but explicitly not resolved. No control, no imaging.
- quote: My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc. Flared up hard in March, could barely sit or stand without pain. Went on for 3 months with zero improvement. Also had a biceps tendon issue for over a year, couldn't curl on the right side. Plus something in the right shoulder that made shoulder press painful. In June I ran BPC-157 and TB-500 for about 6 weeks. Separate, normal doses like everyone recommends, injected into belly fat. 
- hash: `47d7b712d9a9a3ab`

### s33 · x
- title: Elbow tendon pain of months, 2 mg injected locally each day (anecdotal)
- url: https://x.com/Compound_Cowboi/status/2083353093878448335
- summary: Anecdotal, single account, self-reported. Reported benefit at a dose far above the commonly cited range, injected at the site.
- quote: Elbow tendinitis has been killing me for months. Started messing with my lifts and I was getting real tired of it. Been hitting it with 2mg BPC-157 every day, straight into the spot. A few weeks in and it's night and day. Pain is pretty much gone and I'm training normal again. Still got a little ways to go but damn it feels good to not have that constant ache.
- hash: `2161e6bf43045855`

### s34 · x
- title: A two-and-a-half-year knee injury the poster says nothing else fixed (anecdotal)
- url: https://x.com/raymondAjenkins/status/2084117597361189075
- summary: Anecdotal, single account, self-reported. Note the poster was taking two other compounds at the same time, so the effect cannot be attributed.
- quote: Hgh, reta, bpc-157. Bpc helped fix a 2.5 year knee injury surgeons, Drs, and PT could not.
- hash: `0ea12b244b8336f3`

### s35 · x
- title: Lifelong shoulder and joint pain on the BPC-157 plus TB-500 combination — post links a supplier (anecdotal)
- url: https://x.com/BenWolf1425771/status/2083968934064316770
- summary: Anecdotal, single account. Filed with an explicit conflict flag: the post advertises a supplier, which is a reason to discount it rather than exclude it.
- quote: Promise you peptides are No Joke, I used the wolverine stack (BPC-157 and TB-500) to alleviate lifelong shoulder and joint pains, Im sure it has other good health benefits. I found this peptide community on discord, the supplier on there is very reliable
- hash: `2c2e882cb8b43d6b`

### s36 · x
- title: Rotator cuff surgery recommended, two eight-week cycles, surgery avoided — post ends in a follow-me pitch (anecdotal)
- url: https://x.com/michaelo_x/status/2072480753938751554
- summary: Anecdotal, single account. Filed with an explicit conflict flag: the post is promotional and ends by soliciting followers. Also the clearest statement of a commonly used dose and cycle.
- quote: Surgeon told me I needed rotator cuff surgery. A few months later I was back to heavy lifting and never went under the knife... For my shoulder, I ran 500mcg every night, injected subq right into the fat around the injury site. I did an 8 week cycle, took a 2 week break, then ran it a second time. By the end of that second cycle I was already back under heavy weight and surgery wasn't on the table anymore... As far as side effects, I haven't had any. The only things I've hear
- hash: `a3a2b9f49b785f5b`

### s37 · x
- title: Two months, rotator cuff quiet during training, heartburn gone (anecdotal)
- url: https://x.com/Shift_leader06/status/2071665450971181146
- summary: Anecdotal, single account. The reported heartburn change is the only place in this panel that lines up with the animal gut-protection data.
- quote: Took bpc-157 for two months, heartburn basically gone unless I eat chili or something like that right before bed. Rotator cuff injury from jujitsu not bothering me when I lift or roll. Mood stable… like if something happens that would make me mad I let slide
- hash: `0cbb7228485ed962`

### s38 · x
- title: A disc flare that resolved in seven days, with placebo raised by the user himself (anecdotal)
- url: https://x.com/AJA_Cortes/status/1794522474702336108
- summary: Anecdotal, single account, and the most intellectually honest one in the set: three interventions at once, a seven-day window in which a flare commonly settles anyway, and the user naming placebo himself.
- quote: Had a bad disc flare up this past weekend (I had a disc herniation at L5-S1 many years ago, never been the same since) Was staggering around in pain for a day and a half. Decided to try to taking oral BPC157 at 2000mcg daily -Also got two deep tissue massages, and a chiro adjustment. 7 days later, pain free. Did the BPC157 help? Maybe, maybe not. Im always open to possibility of placebo. Regardless, it was a fast recovery
- hash: `8f0eb38d95582b64`

### s39 · x
- title: Ten years of on-and-off use and a flat negative verdict (anecdotal)
- url: https://x.com/LtCrandog/status/2082758463407473109
- summary: Anecdotal, single account. Reported no benefit over the longest exposure in this panel, and new tendon pain appearing during use.
- quote: Appreciate you acknowledging the potential placebo benefits. Been taking bpc157 off and on for over 10 years and really don't think it does much. Apart from not really healing anything I've had random tendinitis pop up even while being on bpc
- hash: `b711610bd7452de2`

### s40 · x
- title: Eight weeks for a shoulder, judged not a success — but stomach problems returned after stopping (anecdotal)
- url: https://x.com/WayneLMarsh/status/2081368522601509373
- summary: Anecdotal, single account. Negative for the injury claim and incidentally supportive of the gut-protection claim — the two things are separable and this account separates them.
- quote: I took BPC-157 for a shoulder injury. After 8 weeks the pain had lessened but I really didn't class it as a success. Came off and about 2 weeks later had problems with my stomach that had disappeared out of my awareness whilst taking BPC. Evaluating on a systemic level has better chance of catching this kind of thing. Sometimes the focus is too narrow.
- hash: `a80d221defb94927`

## Provenance (8 model passes)
- chain valid: yes · head: `e769ba74b23d48e0`

- rewrite · Opus 5 (Claude Code) · 2026-08-04T19:27 · hash `f135f805e925`
- atomize-claims · opus-5 (claude-code) · 2026-08-04T19:34 · hash `43353ca1dc65`
- bind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:48 · hash `75552aad537c`
- backfill-claim-provenance · opus-5 (claude-code) · 2026-08-04T19:51 · hash `c81539e46f72`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:53 · hash `3d721699e064`
- assign-constitution-slots · opus-5 (claude-code) · 2026-08-04T19:56 · hash `b5adb28cc696`
- assign-constitution-slots · opus-5 (claude-code) · 2026-08-04T19:57 · hash `374291f87bef`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:58 · hash `e769ba74b23d`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"bpc-157-vs-nsaids","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest bpc-157-vs-nsaids|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim bpc-157-vs-nsaids|tier|assertion`
- **iMessage ask:** `bpc-157-vs-nsaids|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `bpc-157-vs-nsaids`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/bpc-157-vs-nsaids/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*